Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
A significantly higher number of UGT1A9 polymorphisms was found in the group that did not respond to Mycophenolic acid treatment.
None of the patients with Regorafenib-induced severe toxic hepatitis had CYP3A4 (show CYP3A4 ELISA Kits) gene mutations. Similar polymorphisms in UGT1A9 gene promoter region were found in both patients who presented acute hepatitis.
No association between the UGT1A9 c.98T>C polymorphism and mycophenolic acid plasma levels were found in renal transplant patients.
UGT1A1 (show UGT1A1 ELISA Kits), UGT1A6 (show UGT1A6 ELISA Kits), and UGT1A9 were the chief contributors to the regioselective glucuronidation of diosmetin and chrysoeriol in the liver.
polymorphisms c.98T>C in the UGT1A9 and c.1075A>C in the CYP2C9 (show CYP2C9 ELISA Kits) genes did not affect the pharmacokinetic profile of propofol
Carriers of T-275A and C-2152T single-nucleotide polymorphisms of the UGT1A9 gene promoter region show a greater incidence of death from digestive system cancer after kidney transplantation.
demonstrated the effects of UGT1A9 genetic polymorphisms on MHD plasma concentrations and OXC therapeutic efficacy. Through MHD monitoring, we can predict OXC therapeutic efficacy, which may be useful for the personalization of OXC therapy in epileptic patients
Dimerization changed the chemical regioselectivity, substrate-binding affinity, and enzymatic activity of UGT1A1 (show UGT1A1 ELISA Kits) and UGT1A9 in glucuronidation of quercetin.
UGT1A9 contributes to the in-vitro glucuronidation of arctigenin in liver microsomes.
the in vitro glucuronidation of raloxifene in humans and monkeys was examined using liver and intestinal microsomes and recombinant UGT (show SLC35A2 ELISA Kits) enzymes (UGT1A1 (show UGT1A1 ELISA Kits), UGT1A8 and UGT1A9).
Diabetes mellitus caused a decrease in the activity of Cyp3a11-mediated testosterone-6beta-hydroxylation, but no change in the activity of Cyp3a11-mediated midazolam 1-hydroxylation and an increase in the activity of UGT1a9-mediated propofol O-glucuronidation in db/db (show LEPR ELISA Kits) mice
This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenols.
UDP glycosyltransferase 1 family, polypeptide A9
, UDP-glucuronosyltransferase 1-9
, UDP-glucuronosyltransferase 1A9
, UDP glucuronosyltransferase 1 family, polypeptide A9
, UDP glycosyl transferase 1A9
, UDP-glucuronosyltransferase 1-I
, UDP glycosyltransferase 1 family polypeptide A12
, UDP-glucuronosyltransferase 1-7
, UDP glycosyltransferase 1 family polypeptide A10
, UDP glycosyltransferase 1 family polypeptide A11
, UDP glycosyltransferase 1 family, polypeptide A10